High-risk Stage III colon cancer patients identified by a novel five-gene mutational signature are characterized by upregulation of IL-23A and gut bacterial translocation of the tumor microenvironment

Int J Cancer. 2020 Apr 1;146(7):2027-2035. doi: 10.1002/ijc.32775. Epub 2019 Nov 27.

Abstract

The heterogeneities of colorectal cancer (CRC) lead to staging inadequately of patients' prognosis. Here, we performed a prognostic analysis based on the tumor mutational profile and explored the characteristics of the high-risk tumors. We sequenced 338 colorectal carcinomas as the training dataset, constructed a novel five-gene (SMAD4, MUC16, COL6A3, FLG and LRP1B) prognostic signature, and validated it in an independent dataset from The Cancer Genome Atlas (TCGA). Kaplan-Meier and Cox regression analyses confirmed that the five-gene signature is an independent predictor of recurrence and prognosis in patients with Stage III colon cancer. The mutant signature translated to an increased risk of death (hazard ratio = 2.45, 95% confidence interval = 1.15-5.22, p = 0.016 in our dataset; hazard ratio = 4.78, 95% confidence interval = 1.33-17.16, p = 0.008 in TCGA dataset). RNA and bacterial 16S rRNA sequencing of high-risk tumors indicated that mutations of the five-gene signature may lead to intestinal barrier integrity, translocation of gut bacteria and deregulation of immune response and extracellular related genes. The high-risk tumors overexpressed IL23A and IL1RN genes and enriched with cancer-related bacteria (Bacteroides fragilis,Peptostreptococcus, Parvimonas, Alloprevotella and Gemella) compared to the low-risk tumors. The signature identified the high-risk group characterized by gut bacterial translocation and upregulation of interleukins of the tumor microenvironment, which was worth further researching.

Keywords: colorectal cancer; prognostic signature; tumor microenvironment; tumor mutational profile.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Bacterial Translocation*
  • Biomarkers, Tumor
  • Colonic Neoplasms / diagnosis*
  • Colonic Neoplasms / etiology*
  • Colonic Neoplasms / mortality
  • Female
  • Filaggrin Proteins
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Interleukin-23 Subunit p19 / genetics*
  • Male
  • Metagenomics
  • Middle Aged
  • Mutation*
  • Neoplasm Staging
  • Prognosis
  • Proportional Hazards Models
  • RNA, Ribosomal, 16S
  • Tumor Microenvironment / genetics*

Substances

  • Biomarkers, Tumor
  • FLG protein, human
  • Filaggrin Proteins
  • IL23A protein, human
  • Interleukin-23 Subunit p19
  • RNA, Ribosomal, 16S